NanoViricides Seeks Rare Pediatric Designation to Unlock $150–160M PRV for NV-387
NanoViricides has applied for FDA rare pediatric disease designation for its measles-targeting antiviral candidate NV-387, potentially unlocking a Priority Review Voucher worth up to $160 million upon approval. The designation alongside an orphan drug application is expected to accelerate FDA engagement with more frequent meetings and faster development timelines.
1. Rare Pediatric Disease Designation Application
NanoViricides has filed an FDA request for rare pediatric disease designation for NV-387 following the program’s reinstatement, aiming to secure priority review status and enhanced regulatory support.
2. Priority Review Voucher Opportunity
If approved, NV-387 could earn a Priority Review Voucher valued at $150–160 million, which can expedite other drug reviews or be sold, offering a substantial near-term financial incentive.
3. Orphan Drug Strategy and Timeline Acceleration
The company has also submitted an orphan drug designation for measles, expecting that combined designations will trigger more frequent FDA meetings and streamline development schedules.
4. Focus on Measles Therapeutic Gap
NV-387 is being developed to address measles infections in vulnerable populations, including infants and vaccine non-responders, where no approved antiviral treatments currently exist, highlighting significant unmet need.